Timothy Rolph - 10 Mar 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Scientific Officer
Signature
/s/ Jonathan Young, Attorney-in-Fact
Issuer symbol
AKRO
Transactions as of
10 Mar 2023
Transactions value $
-$26,212
Form type
4
Date filed
14 Mar 2023, 16:19
Previous filing
30 Dec 2022
Next filing
15 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Tax liability -$26.2K -603 -0.32% $43.47 190K 10 Mar 2023 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.